CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients' Survival

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Bladder cancer prognosis remains challenging.
• Identifying reliable prognostic biomarkers is crucial for patient management.
• The role of CD274 (PD-L1) promoter gene methylation in bladder cancer is under investigation.

Purpose of the Study:

• To evaluate the prognostic value of CD274 (PD-L1 promoter gene) methylation in bladder cancer.
• To determine the association between PD-L1 methylation and overall survival (OS).
• To explore PD-L1 methylation as a potential biomarker for immunotherapy response.

Main Methods:

• Utilized the UCSC Xena database for data retrieval.
• Analyzed PD-L1 (CD274) methylation and mRNA expression in bladder cancer.
• Included data from 407 bladder cancer patients.
• Performed multivariate analysis to assess prognostic significance.

Main Results:

• PD-L1 methylation was identified as an independent predictor of OS (P=0.037).
• PD-L1 methylation showed potential as a prognostic biomarker for immunotherapy response.
• No statistically significant association was found between PD-L1 methylation/mRNA expression and chemotherapy response.

Conclusions:

• CD274 (PD-L1 promoter gene) methylation serves as an independent prognostic factor in bladder cancer.
• PD-L1 methylation may guide immunotherapy treatment decisions.
• Further research is warranted to fully elucidate the clinical implications of PD-L1 methylation.